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Background: Formation of asymmetric kinase dimers is required for wt-EGFR activation upon ligand stimulation.
The role of receptor dimerization in oncogenic EGFRvIII mutant activation is not completely understood and the
molecular details of EGFRvIII interactions within homo-dimers and hetero-dimers are not elucidated yet.
Findings: By employing mutations that disrupt the asymmetric kinase dimer interface in EGFRvIII, we demonstrate
that the mechanism of oncogenic EGFRvIII mutant activation is similar to that of the full-length wild-type EGFR.
Surprisingly, the monomeric EGFRvIII lacks autophosphorylation and the formation of asymmetric kinase dimers is
indispensable for oncogenic kinase activation. In addition, we show that ERBB3 can act as an activator of EGFRvIII
by forming asymmetric kinase dimer in a ligand-independent manner. Interestingly, we found that the formation of
asymmetric kinase dimer is dispensable for ERBB3 phosphorylation by the activated EGFR kinase as well as the
ERBB2 kinase thus revealing a novel model for receptor function.
Conclusions: Lateral signaling is a novel mechanism of signal propagation via ERBB3 upon activation by EGFR/ERBB2
kinase even in the absence of their ability to form asymmetric kinase dimers.
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EGFRvIII monomers lack kinase activity
Previous studies reported that EGFRvIII dimers cannot
be detected in cells suggesting that kinase-active mono-
mers of EGFRvIII execute mitogenic signal transduction
[1-4]. This hypothesis is in accordance with the fact that
EGFRvIII lacks the ligand-binding domain, which is crit-
ical for receptor dimerization. On the other hand subse-
quent reports were able to detect EGFRvIII dimers and
could demonstrate that their activity is comparable to
that of the ligand-stimulated wild-type EGFR [5,6]. Thus,
the role of EGFRvIII dimerization for kinase activation is
controversial and not fully elucidated. Recently, Zhang
et al. using an elegant approach were able to demon-
strate that the formation of asymmetric dimers of the
kinase domain are absolutely essential for wt-EGFR acti-
vation upon ligand stimulation [7]. To test if asymmetric* Correspondence: direktion-med1@uniklinik-freiburg.de
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reproduction in any medium, provided the ordimer formation is important for kinase activity we in-
troduced point mutations (Additional file 1) in either the
N-lobe or C-lobe of EGFRvIII and EGFRvIII-D837N
(kinase-dead) (Figure 1A-B, Additional file 2: Figure
S1A). We used cells that lack endogenous EGFR expres-
sion [8,9] (Figure 1A, lane 1). Disruption of the asym-
metric kinase dimer interface by either N-lobe I706Q
mutation (Figure 1A, lane 4) or C-lobe V948R mutation
(Figure 1A, lane 5) indeed abrogated EGFRvIII kinase
activity compared to the unmutated control (Figure 1A,
lane 2). This data indicate that an intact asymmetric kin-
ase dimer interface is essential for EGFRvIII kinase activa-
tion and was an unexpected finding given the previous
observation that the receptor is not able to efficiently form
stable dimers (Figure 1B, Additional file 2: Figure S1A) [1].
To further demonstrate the importance of asymmetric
dimer formation for kinase activity, cells were trans-
fected with a combination of mutants wherein the kinase
activity of a C-lobe mutant (V948R) is rescued in trans
by the kinase-dead (D837N) EGFRvIII either alone
(Figure 1A-B, lane 7) or in combination with the N-lobeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Asymmetric kinase dimer formation is involved in EGFRvIII activation and ERBB3 phosphorylation. (A) EGFRvIII point mutations
were transfected into HEK293 cells either alone or in combinations as indicated by colored circles (lanes 2 to 13). Untransfected cells were taken
as negative control (lane 1). Cell lysis was performed 36 hours after transfection followed by SDS-PAGE. Immunoblotting was performed with
anti-p-EGFR (Y1068) (upper panel), anti-EGFR (second panel), anti-p-STAT5 (third panel) and anti-STAT5 (lower panel) antibodies. (B) Schematic
representation of the most important mechanisms of wild-type and mutant EGFRvIII kinase activation corresponding to the experiments shown
in Figure 1A in lanes 2, 7 and 10. Kinases were labeled black (intact active centre) or red (kinase dead) and yellow (N-lobe mutant) or green (C-lobe
mutant) circles. (C) Wild-type or mutated EGFRvIII kinase (I706Q or V948R) was co-transfected with wild-type ERBB3 in HEK293 cells. After 36 hours,
serum starvation for 12 hours was performed. Cells then were stimulated or not with 50 ng/ml heregulin for 5 minutes before cell lysis was performed.
Immunoprecipitates with anti ERBB3 (upper 2 panels) or whole cell lysates (lower four panels) were resolved by SDS-PAGE and western blotting was
performed with the antibodies indicated. (D) Schematic representation of key kinase domain interactions in receptor homo- and hetero-dimers
corresponding to the experiments shown in Figure 1C in lanes 7, 8, 11 and 12.
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of C-lobe (V948R) mutant could not be rescued by a
kinase-dead C-lobe mutant (D837N +V948R) due to the
disruption of the asymmetric kinase dimer interface
(Figure 1A-B, lane 13). Additional EGFRvIII mutants
with disrupted asymmetric kinase dimer interface both in
wild-type and D837N background were taken as controls
(lanes 6, 8, 9, 11 and 12) to demonstrate the absence of
cis-autophosphorylation (Figure 1A-B, Additional file 2:
Figure S1A). Together these data argue for an important
role of asymmetric dimer formation also for EGFRvIII kin-
ase activation. Furthermore, it shows for the first time thatthe extra-cellular in-frame deletion of the EGFRvIII recep-
tor does not result in an activated monomer as previously
anticipated. A recent study reported the importance of
Cys307 (wild-type EGFR numbering; Cys16 in mature
EGFRvIII mutant) in EGFRvIII receptor dimerization [10].
We thus cloned the C16S mutant into the EGFRvIII/
D837N backbone and tested for its ability to activate the
C-lobe mutated EGFRvIII. As expected, the EGFRvIII/
C16S +D837N mutant was not able to activate the
EGFRvIII/V948R mutant indicating that the receptor
dimerization is indispensable for EGFRvIII activity
(Additional file 2: Figure S1B).
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hetero-dimer
Recently, it was shown that ERBB3 could act as an acti-
vator for the wt-EGFR kinase [11]. However, it is not
known whether oncogenic EGFRvIII is able to form acti-
vating dimers with ERBB3. To test for potential ERBB3/
EGFRvIII interactions, we expressed both constructs in
HEK293 cells, which lack ERBB receptor expression
[8,12] (Figure 1C: lanes 1–2, Additional file 3: Figure
S2A). ERBB3 lacks intrinsic kinase activity [11] and when
expressed alone didn’t cause receptor phosphorylation
even in the presence of it’s ligand heregulin (Figure 1C:
lanes 5–6, Additional file 3: Figure S2A). However, expres-
sion of ERBB3 together with EGFRvIII mutant resulted in
ERBB3 phosporylation indicating that ERBB3 can act as a
substrate for EGFRvIII kinase by forming heterodimers
(Figure 1C-D: lanes 7–8). Interestingly, EGFRvIII-I706Q
(N-lobe) mutant that disrupts asymmetric kinase dimer
formation didn’t result in ERBB3 phosphorylation indicat-
ing that ERBB3 acts as an activator of EGFRvIII kinase
(Figure 1C: lanes 9–10, Additional file 3: Figure S2A).
Moreover, ERBB3 rescued the kinase activity of EGFRvIII-
V948R (C-lobe) mutant thus demonstrating that the
asymmetric kinase dimer interface is similar for both the
EGFRvIII homodimers and EGFRvIII-ERBB3 hetero-
dimers (Figure 1C-D: lanes 11–12). Receptor phos-
phorylation also correlated with the phosphorylation of
downstream targets such as STAT5 indicating that the
asymmetric kinase dimers are indeed functional. The
phenomenon of EGFR kinase activation by asymmetric
kinase dimerization thus seems to be highly conserved
among different members of the EGFR family and differ-
ent types of activating mutations found in human cancers
[7,13]. Since kinase-inactive EGFRvIII is still able to be an
activator for a partner receptor, inhibitor-bound-EGFRvIII
may still activate other receptors of the EGFR family
(ERBB2 or ERBB4). In the setting of EGFR tyrosine kinase
inhibitor (TKI) treatment this may lead to altered signal
transduction and secondary drug resistance. Thus, the ex-
pression of ERBB2, ERBB3 and ERBB4 in EGFR driven
cancer may be important to predict the outcome of TKI
treatment.
Asymmetric kinase dimerization is dispensible for ERBB3
phosphorylation by activated EGFR and ERBB2 kinases
The dynamic role of monomers within an asymmetric
dimer is not completely understood. It has been postu-
lated that reciprocal asymmetric dimer formation, i.e.
the acceptor kinase becomes the activator and vice versa
leads to the full activation of both monomers [14]. It
was also hypothesized that the activation by asymmetric
kinase dimerization may happen in higher-order oligo-
mers [14]. To address this we employed the EGFRvIII-
ERBB3 heterodimer as a model wherein kinaseactivation can be viewed separately from substrate phos-
phorylation due to the differences in both size and the
epitope. A series of EGFRvIII and ERBB3 mutants were
created for this purpose. Consistent with the data shown
in Figure 1C, EGFRvIII was able to phosphorylate
ERBB3 in a ligand independent manner (Figure 2A-B:
lanes 3, 4). ERBB3-V945R was previously shown to dis-
rupt asymmetric kinase dimer formation [11] and as
expected it failed to activate C-lobe (acceptor) mutant
EGFRvIII (Figure 2A: lanes 5, 6, Additional file 3: Figure
S2B). Surprisingly, when expressed together with an “ac-
tivated EGFRvIII receptor homodimer unit”, ERBB3-
V945R was phosphorylated (Figure 2A-B: lanes 7,8). This
phenomenon was not observed when the “kinase-defective
EGFRvIII activation unit” was used (Figure 2A: lanes 9,10,
Additional file 3: Figure S2B) indicating that EGFRvIII is
indeed the kinase. This finding is unexpected since
ERBB3-V945R is defective in forming asymmetric kinase
dimer with either of the EGFRvIII monomers used
(EGFRvIII-D837N/I706Q and EGFRvIII-V948R). Thus,
the lack of ability to act as an activator-kinase did not dis-
qualify C-lobe (V945R) mutant ERBB3 to act as a sub-
strate for EGFRvIII kinase. Symmetric kinase dimers were
reported in EGFR crystals even though they have no role
in kinase activation [7]. To test their role we introduced
mutations (R962E and K970E) that disrupt the symmetric
kinase interface of the activated (acceptor) kinase and
expressed it together with ERBB3. Disruption of sym-
metric kinase dimer interface didn’t abrogate the ability
of activated EGFRvIII kinase to phosphorylate ERBB3
(Figure 2C). Interestingly, a slight decrease in ERBB3
phosphorylation was observed upon heregulin stimula-
tion (Figure 2C). It was previously shown that heregulin
stimulation results in the destabilization of ERBB3 olig-
omers but not of receptor dimers [15]. Thus, the ob-
served reduction of ERBB3 phosphorylation upon
heregulin stimulation in this particular setting might be
due to the disruption of higher-order oligmers involving
ERBB3 receptors.
To test if similar mechanisms are involved in ERBB3
phosphorylation by the full-length receptor, we expressed
both wild-type and C-lobe mutant ERBB3 together with
the wild-type EGFR. Interestingly, full length, wild-type
EGFR phosphorylated both wild-type as well as the C-lobe
mutant ERBB3 upon EGF stimulation but not upon
heregulin stimulation (Figure 2D). EGFR-L858R, a consti-
tutively active mutant that was reported in NSCLC pa-
tients, also phosphorylated both wt and C-lobe mutant
ERBB3 in a ligand-independent manner (Figure 2E). These
results imply that it is not necessary for ERBB3 to be part
of an asymmetric kinase dimer to be activated by EGFR
kinase. The phosphorylation of ERBB3 by EGFR kinase
despite the inability to form neither asymmetric nor sym-
metric dimers of kinase domain indicates that the
Figure 2 Asymmetric kinase dimer formation is dispensable for ERBB3 activation by EGFR kinase. (A) Indicated EGFRvIII and ERBB3
constructs were transfected into HEK293 cells. After 36 hours, stimulation with 50 ng/ml of heregulin for 5 minutes was performed. Cells were
then lysed and subjected to immunoprecipitation using anti-ERBB3 antibody. Immunoblotting was performed on ERBB3 immunoprecipitates with
indicated antibodies (top 2 panels). Whole cell lysates (input) were subjected to western blotting with indicated antibodies (lower 3 panels).
(B) Schematic representation of receptor interactions corresponding to the experiments shown in Figure 2A (lanes 3, 4, 7 and 8). (C) Indicated
EGFR and ERBB3 mutants were transfected into HEK293 cells followed by serum starvation and heregulin (50 ng/ml) stimulation for 5 minutes.
Immunoblotting on ERBB3 immunoprecipitates was performed with indicated antibodies (upper 2 panels). Immunoblotting of whole cell lysates
(input) was performed with indicated antibodies (lower 2 panels). (D) Wild-type EGFR was co-transfected with either wild-type or C-lobe mutant
(V945R) ERBB3 into HEK293 cells. After 36 hours, cells were serum starved for 12 hours followed by stimulation with EGF (25 ng/ml) or heregulin
(50 ng/ml) for 5 minutes. Cells were then lysed and subjected to ERBB3 immunoprecipitation. SDS-PAGE and immunoblotting on ERBB3
immunoprecipitates was performed with indicated antibodies (upper 2 panels). Western blotting on whole cell lysates (input) was performed
with indicated antibodies (lower 2 panels). (E) EGFR-L858R was co-transfected with either wild-type or C-lobe mutant (V945R) ERBB3 into HEK293
cells. After 36 hours, cells were serum starved for 12 hours followed by stimulation with EGF (25 ng/ml) or heregulin (50 ng/ml) for 5 minutes. Cells
were then lysed and subjected to ERBB3 immunoprecipitation. SDS-PAGE and immunoblotting on ERBB3 immunoprecipitates was performed with
indicated antibodies (upper 2 panels). Western blotting on whole cell lysates (input) was performed with anti-EGFR antibody.
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the acceptor kinase close enough to phosphoryate it’s sub-
strate (Figure 3A). Moreover, ERBB2 phosphorylated both
the wild-type and C-lobe mutant ERBB3 (Figure 3B) indi-
cating that the observed mechanism is conserved among
different members of the ERBB family.Activated ERBB3 potentiates the transforming ability of
EGFR and ERBB2
To test the functional role of kinase activation within
different ERBB receptor combinations, we employed a
competition assay using Ba/F3 cells. Ba/F3 cells lack
ERBB receptor expression and were previously used to
Figure 3 Activated EGFR/ERBB2 kinase phosphorylates ERBB3 independent of asymmetric kinase dimer formation. (A) Schematic
representation of two hypothetic mechanisms potentially involved in activator function-defective EGFR/ERBB3 phosphorylation by activated EGFR:
The activated EGFR dissociates from the activator kinase to phosphorylate another inactive (activator function-defective) EGFR (i) or ERBB3 (ii)
receptor. Alternatively, activated EGFR may form higher-order oligomer or hetero-tetramer complexes to cause phosphorylation of activator
function-defective ERBB receptors (iii). (B) HEK293 cells were transfected with wild-type ERBB2 either alone or together with WT or mutant ERBB3
(V945R). After 36 hours, cells were serum starved for 12 hours followed by stimulation with 50 ng/ml heregulin for 5 minutes as indicated. Cells
were then lysed in TMNSV buffer [16]. Cells lysates were subjected to immunoprecipitation using rabbit anti-ERBB3 antibody and immunoblotting
was performed using mouse anti-phospho-tyrosine and mouse anti-ERBB3 antibodies (upper 2 panels). Western blotting on whole cell lysates
(input) was performed with anti-pERBB2 and anti-ERBB2 antibodies (lower 2 panels).
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[8,9,12]. Ba/F3 cells require IL-3 for survival and intro-
duction of oncogenes into these cells confer cytokine-
independence on these cells [8,9,12]. Thus, we employed
Ba/F3 cells to test the physiological role of ERBB3 phos-
phorylation by ERBB receptors in different combinations.
Stable cell lines expressing either wild-type or C-lobe mu-
tant ERBB3 (V945R) were established for this purpose
(Figure 4A). Both wild-type and C-lobe mutant ERBBs
(EGFR, EGFRvIII and ERBB2) were transduced in to ei-
ther parental Ba/F3 cells (Figure 4B-E: panel i) or Ba/F3
cells that stably express ERBB3 receptors (Figure 4B-E:
panels ii and iii). Since EGFR, EGFRvIII and ERBB2 were
expressed from bi-cistronic vectors that co-express either
GFP or YFP, the signaling strength of receptor combina-
tions was measured as the rate of outgrowth of transduced
cells over untransduced cells [9,12]. EGFRvIII transformed
Ba/F3 cells to cytokine-independence as reported previ-
ously (Figure 4B: i) [8,9]. The transformation of Ba/F3
cells by EGFRvIII is potentiated by the co-expression of
ERBB3 receptor indicating an important role of ERBB3
phosphorylation (Figure 4B: ii, iii). As expected, the
C-lobe mutant EGFRvIII-V948R didn’t transform Ba/
F3 cells (Figure 4C: i). However, expression of ERBB3
receptor conferred IL3-independence on Ba/F3 cellsthat stably express EGFRvIII-V948R indicating the
functional role of asymmetric kinase dimer formation
(Figure 4C: ii). EGFRvIII-V948R however failed to trans-
form Ba/F3 cells that expressed ERBB3-V945R even after
heregulin stimulation indicating the importance of asym-
metric kinase dimer interface in the activation of receptor
(Figure 4C: iii). Moreover, transformation of Ba/F3 cells to
IL-3 independence by full-length wild-type EGFR was
also potentiated by ERBB3 upon heregulin stimulation
(Figure 4D: i, ii). Even though similar patterns were
seen with cells expressing ERBB3-V945R, the transform-
ation ability was relatively weak compared to that of
cells expressing wild-type ERBB3 (Figure 4D: ii, iii).
Similar observations were made with the combination of
ERBB2 and ERBB3 receptors (Figure 4E: i - iii) indicating
that the signaling strength resulting from the lateral sig-
naling is weaker compared to that of the ‘activating asym-
metric kinase dimer’ unit.
Conclusions
Formation of asymmetric kinase dimer is essential for
both the constitutive activation of oncogenic EGFR as
well as the ligand-stimulated wild-type EGFR. However,
phosphorylation of ERBB3 by the activated EGFR or
ERBB2 kinase may occur in higher order oligomers in
Figure 4 Functional analysis of ERBB heterodimers. (A) Ba/F3 cells stably expressing indicated ERBB3 receptors were lysed and western
blotting was performed with anti-ERBB3 and anti-beta-actin antibodies. Untransfected Ba/F3 cells were taken as a negative control. (B-E) Ba/F3
cell lines described above with or without stable expression of ERBB3 constructs were additionally infected with MSCV-GFP-EGFRvIII (B: i: control,
ii: ERBB3-WT, iii: ERBB3-V945R), MSCV-GFP-EGFRvIII/V948R (C: i: control, ii: ERBB3-WT, iii: ERBB3-V945R), MSCV-YFP-EGFR (D: i: control, ii: ERBB3-WT, iii:
ERBB3-V945R) or MSCV-GFP-ERBB2 (E: i: control, ii: ERBB3-WT, iii: ERBB3-V945R). Cells were then cultured with or without the indicated cytokines
(IL-3, EGF (25 ng/ml) or heregulin (50 ng/ml). The Percentage of GFP-positive (EGFRvIII or ERBB2) or YFP (EGFR-WT)-positive cells was measured by
FACS analysis at the indicated time points.
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Thus, asymmetric kinase dimer formation plays a differ-
ential role in EGFR receptor activation and ERBB3 phos-
phorylation. Recent studies have implicated the role of
ERBB3 as a critical heterodimeric partner for both EGFR
and ERBB2 in drug resistance [17]. Since the formation
of receptor complexes is important for their activity, the
use of antibodies that target ERBB receptors either alone
or in combination with ERBB inhibitors might abrogate
the development of secondary drug resistance.
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Additional file 2: Figure S1. (A) Schematic representation of the
mechanism of wild-type or mutant EGFRvIII interactions for
corresponding lanes in Figure 1A (numbered 2 to 13). Kinases were
labeled with black (intact active centre) or red (kinase dead) and yellow
(N-lobe mutant) or green (C-lobe mutant) circles. Intact or rescued kinase
activity is represented by a phospho-tyrosine (P). (B) Wild-type (WT) or
mutated EGFRvIII (KD-Kinase defective) were transfected into HEK293 cells
either alone or in combinations as indicated. Untransfected cells (UT)
were taken as a negative control (lane 1). Cell lysis was performed 36
hours after transfection followed by SDS-PAGE. Immunoblotting was
performed with anti-p-EGFR (Y1068) and anti-EGFR antibodies.
Additional file 3: Figure S2. (A) Schematic representation of receptor
interactions shown in Figure 1B. (B) Schematic representation of receptor
interactions in the setting of both homo- and hetero-dimers. Numbers
correspond to lanes in the Figure 2A.
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